Longs 2 HUGE prs! , leaving in 5 mins for the week but WOW and WOW, 2 massive press releases out! WOW The huge Delta deal was contingent on the sales license, they just got it!! thats massive. And the RS change to 1-5 thats also massive!! what a great way to leave on a boat trip!! stay the course longs, common sense.
Vancouver, BC, January 21, 2019 - INVICTUS MD STRATEGIES CORP. ("Invictus" or the "Company") (TSXV: GENE; OTCQX: IVITF; FRA: 8IS1) announced today an update to its intention to proceed with a consolidation of its issued and outstanding shares with a newly proposed reduced share consolidation ratio of one new share for every five old shares (1:5) in connection with its proposed listing on Nasdaq Stock Market LLC ("Nasdaq"). The proposed reduced share consolidation ratio replaces the original consideration on the basis of one new share for seven old shares (1:7) (see press release dated January 17, 2019).
The purpose of the consolidation is to increase the Company’s common share price to be in compliance with Nasdaq’s minimum share price listing requirement of USD $3.00 (CAD $3.98). Management believes this reduced ratio is sufficient to achieve Nasdaq’s minimum threshold. At Friday’s closing share price of CAD 1.06 (USD 0.80) on January 18, 2019, a 5:1 consolidation represents a new Company share valued at CAD 5.30 (US 3.99).
Most importantly, while investors will hold fewer Invictus shares after the consolidation, each shareholder’s total invested value, percentage ownership in the Company and proportional voting power will remain unchanged.
The United States represents the deepest pool of investor capital in the world with Nasdaq featuring heavily. Invictus’ intended participation on the Nasdaq represents a move to increase its global visibility and liquidity, and for inclusion into indices which are tracked by buy-side institutions like the Standard & Poor’s and Russell indexes.
In addition to the intended Nasdaq listing, Invictus’ shares will continue to trade on the TSX Venture Exchange under the ticker symbol "GENE", and on the Frankfurt Stock Exchange under the ticker symbol "8IS1".
Vancouver, BC, January 21, 2019 - INVICTUS MD STRATEGIES CORP. ("Invictus" or the "Company") (TSXV: GENE; OTCQX: IVITF; FRA: 8IS1) is pleased to announce that the Company’s wholly-owned subsidiary 0989561 B.C. Ltd. ("Canandia") has received a sales license for its Delta location (the “Delta Facility”) from Health Canada effective January 18, 2019, pursuant to the Access to Cannabis for Medical Purposes Regulations (“ACMPR”). The Delta Facility includes a cultivation, production and research facility, designed to highlight our capabilities as producers and breeders of superior cannabis strains.
Canandia’s second asset is located in Mission (the "Mission Location"), British Columbia. The Mission Location includes 32 acres of buildable land, expandable up to 1 million square feet of production capacity under one Cannabis Act and Cannabis Regulations license. The Mission Location taps into wholesale energy costs with 38 MG Watt service at the property line, and boasts access to underground aquifers, making it a strategically attractive and cost competitive addition to Invictus' current cultivation footprint once developed and commissioned.
“We are thrilled to have achieved another major milestone with our second sales license awarded by Health Canada,” said George E. Kveton, President and CEO of Invictus. “We have hit the ground running in 2019, remaining laser focused on our objective to bring new facilities online to cultivate unique strain varieties required for our medical and adult use recreational product portfolio.”
“I am exceptionally proud of our in-house Pharmaceutical Regulatory Compliance Team today,” said Alon Amit CEO of Canandia. “Dr Jaclyn Thompson, Quality Assurance Supervisor, and Director of Research, and her team are behind the issuance of our sales license months ahead of schedule, and the smooth successful migration of our license issued under the ACMPR to the Cannabis Act and its regulations. We look forward to supplying the Canadian medical and recreational markets with our menu of exotic cannabis strains”
Canandia represents the Company's third cultivation license and second sales license issued by Health Canada under the Cannabis Act and Cannabis Regulations. Invictus' production footprint includes licensed cannabis operations in British Columbia, Alberta and Ontario.
AI
